Data from the pivotal COMET clinical trials reveal how the first topical ocular neuromodulator approved for DED—TRYPTYR (acoltremon ophthalmic solution) 0.003%—delivers a rapid and lasting increase in natural tear production.

John Hovanesian, MD
Marjan Farid, MD
Nate Lighthizer, OD 
Selina McGee, OD